• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Vor Biopharma Inc.

    9/25/25 8:34:12 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VOR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Vor Biopharma Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    929033207

    (CUSIP Number)


    09/18/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    929033207


    1Names of Reporting Persons

    Venrock Healthcare Capital Partners III, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    760,699.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    760,699.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    760,699.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    929033207


    1Names of Reporting Persons

    VHCP Co-Investment Holdings III, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    760,699.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    760,699.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    760,699.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    929033207


    1Names of Reporting Persons

    Venrock Healthcare Capital Partners EG, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    760,699.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    760,699.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    760,699.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    929033207


    1Names of Reporting Persons

    VHCP Management III, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    760,699.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    760,699.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    760,699.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    929033207


    1Names of Reporting Persons

    VHCP Management EG, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    760,699.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    760,699.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    760,699.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    929033207


    1Names of Reporting Persons

    Nimish Shah
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    760,699.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    760,699.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    760,699.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    929033207


    1Names of Reporting Persons

    Bong Y. Koh
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    760,699.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    760,699.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    760,699.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Vor Biopharma Inc.
    (b)Address of issuer's principal executive offices:

    500 Boylston Street, Suite 1350, Boston, MA, 02116.
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") are: Venrock Healthcare Capital Partners III, L.P. ("VHCP III") VHCP Co-Investment Holdings III, LLC ("VHCP Co-Investment III") Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG") VHCP Management III, LLC ("VHCP Management III") VHCP Management EG, LLC ("VHCP Management EG") Nimish Shah ("Shah") Bong Koh ("Koh") The Reporting Persons are members of a group for the purposes of this Schedule 13G.
    (b)Address or principal business office or, if none, residence:

    New York Office: 7 Bryant Park, 23rd Floor New York, NY 10018 Palo Alto Office: 3340 Hillview Avenue Palo Alto, CA 94304
    (c)Citizenship:

    All of the entities were organized in Delaware. Shah and Koh are both United States citizens.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    929033207
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. The Reporting Persons' ownership of the Issuer's securities consists of (i) 116,542 shares of the Issuer's common stock and pre-funded warrants (the "Pre-Funded Warrants") exercisable for up to 1,048,950 shares of common stock held by VHCP III; (ii) 11,649 shares of the Issuer's common stock and Pre-Funded Warrants exercisable for up to 104,850 shares of common stock held by VHCP Co-Investment III; and (iii) 371,775 shares of the Issuer's common stock and Pre-Funded Warrants exercisable for up to 3,346,200 shares of common stock held by VHCP EG. The Pre-Funded Warrants contain a provision (the "Beneficial Ownership Blocker"), which precludes the exercise of the Pre-Funded Warrants to the extent that, following exercise, VHCP III, VHCP Co-Investment III and VHCP EG, together with their affiliates and other attribution parties, would own more than 9.99% of the outstanding shares of common stock. VHCP III, VHCP Co-Investment III and VHCP EG are currently prohibited from exercising the Pre-Funded Warrants to the extent that such exercise would result in beneficial ownership of more than 760,699 shares of common stock. VHCP Management III is the general partner of VHCP III and the manager of VHCP Co-Investment III. VHCP Management EG is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCP Management III and VHCP Management EG.
    (b)Percent of class:

    Due to the Beneficial Ownership Blocker listed in the Pre-Funded Warrants, each Reporting Person's beneficial ownership percentage is 9.99%. Such percentage is based upon the sum of (i) 6,853,907 shares of common stock outstanding as of September 18, 2025, as reported in the Issuer's Registration Statement on Form S-3 filed with the Securities and Exchange Commission (the "SEC") on September 24, 2025; (ii) 499,966 shares of common stock issued subsequent to September 18, 2025 upon the exercise of Pre-Funded Warrants by the Reporting Persons; and (iii) 260,733 shares of common stock issuable upon the exercise of the Pre-Funded Warrants. Due to field limitations of the EDGAR filing system, the percentage listed in Row 11 of each Reporting Person's cover page has been rounded down to 9.9%.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.

     (ii) Shared power to vote or to direct the vote:

    Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Venrock Healthcare Capital Partners III, L.P.
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By VHCP Management III, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
    Date:09/25/2025
     
    VHCP Co-Investment Holdings III, LLC
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By VHCP Management III, LLC, its Manager, By Sherman G. Souther, Authorized Signatory
    Date:09/25/2025
     
    Venrock Healthcare Capital Partners EG, L.P.
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By VHCP Management EG, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
    Date:09/25/2025
     
    VHCP Management III, LLC
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By Sherman G. Souther, Authorized Signatory
    Date:09/25/2025
     
    VHCP Management EG, LLC
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By Sherman G. Souther, Authorized Signatory
    Date:09/25/2025
     
    Nimish Shah
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By Sherman G. Souther, Attorney-in-fact
    Date:09/25/2025
     
    Bong Y. Koh
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By Sherman G. Souther, Attorney-in-fact
    Date:09/25/2025
    Exhibit Information

    Exhibit 24.1 Power of Attorney for Bong Koh Exhibit 24.2 Power of Attorney for Nimish Shah Exhibit 99.1 Joint Filing Agreement

    Get the next $VOR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VOR

    DatePrice TargetRatingAnalyst
    9/24/2025$55.00Hold → Buy
    Stifel
    6/30/2025$3.00Neutral → Buy
    H.C. Wainwright
    7/26/2022$18.00Outperform
    Wedbush
    4/27/2022$6.00Neutral
    Goldman
    12/17/2021$26.00Buy
    HC Wainwright & Co.
    12/3/2021$38.00Outperform
    Robert W. Baird
    12/3/2021$38.00Outperform
    Baird
    12/2/2021$30.00Outperform
    Oppenheimer
    More analyst ratings

    $VOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Vor Biopharma upgraded by Stifel with a new price target

    Stifel upgraded Vor Biopharma from Hold to Buy and set a new price target of $55.00

    9/24/25 7:54:22 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Biopharma upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Vor Biopharma from Neutral to Buy and set a new price target of $3.00

    6/30/25 7:56:45 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wedbush initiated coverage on Vor Biopharma with a new price target

    Wedbush initiated coverage of Vor Biopharma with a rating of Outperform and set a new price target of $18.00

    7/26/22 8:25:46 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer

    CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer. Dr. Khan joins Vor Bio with over two decades of experience spanning medical affairs, commercial, and R&D functions. He has overseen more than 40 development programs in neurology, immunology, and infectious diseases, and successfully guided seven U.S. and global product launches in rare neurology and immunology indications. Most recently, Dr. Khan was Head of Neuromuscular Therapeutic Area, Medical Affairs at argenx, where h

    9/23/25 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

    YANTAI, China, Sept. 17, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-target fusion protein innovative drug independently developed by RemeGen) for the treatment of generalized myasthenia gravis (gMG) was selected as an oral presentation at the 2025 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. The meeting will be held from October 29 to November 1, 2025, local time, at the Hilton San Francisco Union Square in California, USA.

    9/17/25 9:00:00 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

    CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that 48-week clinical data from the Phase 3 study in China evaluating telitacicept in adults with generalized myasthenia gravis, a study sponsored by Vor's collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as an oral presentation at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, being held October 29 to November 1, 2025, at the Hilton San Francisco Union Square in San Francisco, California. Oral Presentation DetailsAbstract Title: Efficacy and Saf

    9/17/25 4:15:00 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Vor Biopharma Inc.

    SCHEDULE 13G - Vor Biopharma Inc. (0001817229) (Subject)

    9/25/25 8:34:12 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Vor Biopharma Inc.

    S-8 - Vor Biopharma Inc. (0001817229) (Filer)

    9/24/25 4:59:12 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by Vor Biopharma Inc.

    S-3 - Vor Biopharma Inc. (0001817229) (Filer)

    9/24/25 4:57:17 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Reprogrammed Interchange Llc bought 38,974,101 shares (SEC Form 4)

    4 - Vor Biopharma Inc. (0001817229) (Issuer)

    1/2/25 7:42:04 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Ra Capital Management, L.P.

    4 - Vor Biopharma Inc. (0001817229) (Issuer)

    9/22/25 4:56:52 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Reprogrammed Interchange Llc sold $688,853 worth of shares (447,278 units at $1.54), decreasing direct ownership by 1% to 32,781,209 units (SEC Form 4)

    4 - Vor Biopharma Inc. (0001817229) (Issuer)

    9/18/25 8:40:18 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Reprogrammed Interchange Llc sold $1,703,971 worth of shares (984,805 units at $1.73), decreasing direct ownership by 3% to 33,228,487 units (SEC Form 4)

    4 - Vor Biopharma Inc. (0001817229) (Issuer)

    9/15/25 5:17:28 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vor Biopharma Inc.

    SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

    11/14/24 4:33:50 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Vor Biopharma Inc. (Amendment)

    SC 13D/A - Vor Biopharma Inc. (0001817229) (Subject)

    2/14/24 4:17:24 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Vor Biopharma Inc. (Amendment)

    SC 13G/A - Vor Biopharma Inc. (0001817229) (Subject)

    2/14/24 4:08:06 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Leadership Updates

    Live Leadership Updates

    View All

    Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer

    CAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer. Dr. Khan joins Vor Bio with over two decades of experience spanning medical affairs, commercial, and R&D functions. He has overseen more than 40 development programs in neurology, immunology, and infectious diseases, and successfully guided seven U.S. and global product launches in rare neurology and immunology indications. Most recently, Dr. Khan was Head of Neuromuscular Therapeutic Area, Medical Affairs at argenx, where h

    9/23/25 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

    CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Adi Osovsky, S.J.D. as General Counsel. Dr. Osovsky brings 17 years of corporate counsel and law firm experience in the biotechnology and pharmaceutical sectors. "We are delighted to welcome Adi to Vor Bio at this important stage in our growth," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. "Adi's proven experience advising public biopharmaceutical companies on governance, compliance, and strategic transactions makes her an outstanding addition to our leadersh

    9/2/25 8:00:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

    CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Dallan Murray as Chief Commercial Officer, effective immediately. "We're thrilled to welcome Dallan to Vor Bio at this important inflection point," said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. "His track record of building high-performing commercial organizations and executing successful product launches will be instrumental as we prepare for potential commercialization of telitacicept and shape our broader growth strategy." Mr. Murray brings more than 25 yea

    8/4/25 8:30:53 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VOR
    Financials

    Live finance-specific insights

    View All

    Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

    CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value.   These strategic alternatives could include, among other alternatives, a potential sale of assets of the Company, a potential licensing of assets of the Company, a sale of the Company, a business combination, a merger or other strategic action. The Company

    5/8/25 8:30:15 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

    Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue to demonstrate engraftment, shielding, and broadened therapeutic windowCompany has received supportive feedback from the FDA regarding a registrational clinical trial design CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data, which was presented in a post

    12/9/24 7:30:00 AM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies

    Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with significant potential opportunities across oncology, gene therapy, and autoimmune disorders CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic wind

    9/5/24 4:01:00 PM ET
    $VOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care